Actualités Claritas Pharmaceuticals Inc - CLAS | Actions TSX Venture Exchange

Claritas Announces Approval from OTC to Up-List to OTCQB

SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

SAN FRANCISCO, CA and TORONTO, ON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX...

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

SAN FRANCISCO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE:...

Claritas Provides Update Regarding Phase 1 Clinical Study

SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE:...

Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB

SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE:...

Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC:...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Claritas Pharmaceuticals Inc (CLAS)

Outils de qualité professionnelle, pour des investisseurs individuels.

CLAS Actualités

Claritas Announces Approval from OTC to Up-List to OTCQB

Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Claritas Provides Update Regarding Phase 1 Clinical Study

Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB

Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Claritas Pharmaceuticals Inc (CLAS) Actualités

Claritas Pharmaceuticals Inc (CLAS)

Outils de qualité professionnelle, pour des investisseurs individuels.

CLAS Actualités

Claritas Announces Approval from OTC to Up-List to OTCQB

Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Claritas Provides Update Regarding Phase 1 Clinical Study

Claritas Announces Engagement of B. Riley Securities as Sponsor for the Company’s Planned Up-Listing of its Securities to the OTCQB

Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités